Genetic Technologies
Genetic Technologies (ASX: GTG, NASDAQ: GENE) is a genetic testing business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of DNA on health.
Genetic Technologies: U.S. company awarded non-exclusive access to non-coding DNA technology
Monday, February 06, 2012 by Angela Kean
Genetic Technologies (ASX: GTG, NASDAQ: GENE) has entered into a Settlement and License Agreement with Colorado-based Eurofins STA Laboratories, which has been granted non-exclusive rights to a number of Genetic’s patents covering its non-coding DNA technology.
The agreement provides Eurofins STA Laboratories non-exclusive access to Genetic’s non-coding DNA technology for its products and services.
Genetic is in ongoing discussions with companies relating to the use of its non-coding DNA technology.
Last month the company received a price and volume query from the ASX after its shares hit a A$0.155 intra-day high, a 48% jump on the closing price on Wednesday 25 January.
Highlighting how Genetic Technologies continues to move forward, in December last year the company entered an agreement with German diagnostic product developer AutoImmun Diagnostika, which has also been granted non-exclusive rights to a number of Genetic’s patents covering its non-coding DNA technology.
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
